Harderwijk
Harderwijk
Harderwijk, Netherlands44 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies | Solid Tumors | Recruiting | Phase 2 | 2026-10-09 | NCT07415031 | |
| A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, vascular disorder | Recruiting | Phase 3 | 2026-10-08 | NCT07613294 | |
| Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | Arterial Occlusive Diseases, Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, nutritional disorder, obesity disorder, overnutrition, vascular disorder | Recruiting | Phase 3 | 2026-10-08 | NCT07037433 | |
| A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-10-08 | NCT06292013 | |
| Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-10-07 | NCT06890598 | |
| A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thoracic Neoplasms, bronchial disorder, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-10-07 | NCT06119581 | |
| A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-10-06 | NCT06793215 | |
| Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) | Neoplasms by Site, Thoracic Neoplasms, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-10-06 | NCT06635824 | |
| LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC | Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-10-06 | NCT06216301 | |
| Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 3 | 2026-10-05 | NCT06959095 | |
| Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-10-05 | NCT03820063 | |
| Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer. | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-10-01 | NCT03283384 | |
| A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-09-28 | NCT04988295 | |
| A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-09-28 | NCT04487080 | |
| A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-09-25 | NCT05920356 | |
| Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma | B-cell neoplasm, Cardiotoxicity, Chemically-Induced Disorders, Drug-Related Side Effects and Adverse Reactions, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, diffuse large B-cell lymphoma, heart disorder, heart failure, histiocytosis, immune system disorder, immunoproliferative disorder, injury, interdigitating dendritic cell sarcoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, neoplasm, radiation injury | Recruiting | Phase 3 | 2026-09-23 | NCT06220032 | |
| A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-09-16 | NCT06497556 | |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-09-16 | NCT04613596 | |
| Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin | cardiovascular disorder, heart disorder, heart failure | Recruiting | Phase 3 | 2026-09-15 | NCT06677060 | |
| Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) | Non-small Cell Lung Cancer NSCLC | Active, not recruiting | Phase 2 | 2026-09-11 | NCT03775486 | |
| HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy | EGFR Exon 19 Deletion; EGFR L858R; Nonsquamous Non-small Cell Lung Cancer | Active, not recruiting | Phase 3 | 2026-08-27 | NCT05338970 | |
| Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-08-26 | NCT04656652 | |
| Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, esophageal cancer, esophageal disorder, neoplasm | Active, not recruiting | Phase 2 | 2026-08-21 | NCT03764553 | |
| Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 / Phase 3 | 2026-07-01 | NCT04655976 | |
| A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, cardiovascular disorder, chronic renal failure syndrome, hypertensive disorder, kidney disorder, kidney failure, urinary system disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-06-26 | NCT06268873 |